Melanoma (Skin Cancer)
EA6191 / BAMM2
The BAMM2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with elevated LDH
Physician and Research Staff Educational Material
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material. Scroll down for patient educational material
Patient Educational Material
Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material.
Recruitment/Awareness Promotional Material
Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. Note: this content can be utilized for site-specific and community outreach (e.g., webpages, informational handouts, posters, etc.) to encourage potential participants to talk with their doctor, or to contact a site where the study is open for more information. The content may not be modified, and the entities who implement this plan (not including clinical staff) must refrain from direct engagement with patients, except to encourage them to speak with their doctor, or to direct them to the trial page on ECOG-ACRIN or Cancer.gov.